Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma

The hypoxic status of cancer tumour is disparate within tumour microenvironment and is considered as the main cause of treatment resistance. Chondrosarcoma, a type of bone cancer, combines heterogonous tumour microenvironment and resistance to therapies. We aimed to image tumour microenvironment response to hypoxia activated prodrug therapy with Evofosfamide (TH-302) on a rat chondrosarcoma model thanks to an original multimodal imaging strategy. Bimodal imaging strategy consisted of nuclear imaging and MRI on TH-302 treated and control animals. To monitor TH-302 effects on tumour growth and structure, we measured T2 and ADC by MRI and we used ¹⁸F-FDG to explore tumour metabolism. ¹⁸F-FMISO and APT to Guanidyl ratio CEST MRI evaluated hypoxic status. Proteoglycans in the extracellular matrix were explored in vivo by a radiotracer targeting proteoglycans (^99mTc-NTP 15 - 5) and GAG CEST MRI. Immunohistochemistry, biochemical assays and RNA sequencing were performed to confirm in vivo observations.

TH-302 demonstrated a strong efficacy on tumour structure with a reduction of its volume of 75% at the end of the protocol, a modification of the tumour microstructures and a decreased of both cellularity and cell proliferation. The drug also modified the tumour metabolisms as shown by ¹⁸F-FDG PET and GLUT-1 staining for the energetic one, CEST-MRI and pimonidazole for the hypoxic status and ^99mTc-NTP 15 - 5 SPECT and sGAG assay for proteoglycans. Genomic analysis shown changes in gene expression related to therapy.

TH-302 shows an in vivo anti-tumour activity in chondrosarcoma. Our multimodal imaging approach allows monitoring complex exchanges between tumour cells and their neighboring under therapy.